OverviewSuggest Edit

Amphastar Pharmaceuticals is a pharmaceutical company engaged in the development, manufacturing, and marketing of generic and proprietary injectable, intranasal, and inhalation products, as well as insulin active pharmaceutical ingredient (API). Its capabilities include characterizing complex molecules, analyzing and synthesizing peptides and proteins, conducting immunogenicity studies, engineering particles, and improving drug delivery through sustained-release technology. The company is able to develop and manufacture a range of dosage formulations, including solutions, emulsions, suspensions, and lyophilized products, as well as products administered via pre-filled syringes, vials, nasal sprays, metered dose inhalers, or MDIs, and dry powder inhalers, or DPIs. Amphastar operates through two segments: finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets, and distributes enoxaparin, naloxone, phytonadione, lidocaine, medroxyprogesterone acetate, Primatene Mist, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development.

TypePublic
Founded1996
HQRancho Cucamonga, CA, US
Websiteamphastar.com
Employee Ratings2.7
Overall CultureF

Latest Updates

Employees (est.) (Dec 2019)2,027(-2%)
Job Openings9
Revenue (FY, 2020)$349.8 M(+9%)
Share Price (Apr 2021)$18.1(-1%)
Cybersecurity ratingBMore

Key People/Management at Amphastar Pharmaceuticals

Jack Y. Zhang

Jack Y. Zhang

Chief Executive Officer, President, Chief Scientific Officer, and Director
Mary Z. Luo

Mary Z. Luo

Chief Operating Officer, Chief Scientist, and Chairman of the Board of Directors
Jacob Liawatidewi

Jacob Liawatidewi

Executive VP of Corporate Administration Center, Sales, and Marketing
Richard Koo

Richard Koo

Director
Richard Prins

Richard Prins

Director
Howard Lee

Howard Lee

Director
Show more

Amphastar Pharmaceuticals Office Locations

Amphastar Pharmaceuticals has offices in Rancho Cucamonga, Nanjing Shi and Éragny-sur-Epte
Rancho Cucamonga, CA, US (HQ)
11570 6th St
Nanjing Shi, CN
5 Xinghe Rd, Qixia Qu
Éragny-sur-Epte, FR
1 Route Nationale 15 Paris Dieppe
Show all (3)

Amphastar Pharmaceuticals Financials and Metrics

Amphastar Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Amphastar Pharmaceuticals's revenue was reported to be $349.85 m in FY, 2020
USD

Revenue (FY, 2020)

349.8m

Gross profit (FY, 2020)

143.3m

Gross profit margin (FY, 2020), %

41%

Net income (FY, 2020)

1.1m

EBIT (FY, 2020)

11.0m

Market capitalization (1-Apr-2021)

858.1m

Closing stock price (1-Apr-2021)

18.1

Cash (31-Dec-2020)

92.6m

EV

832.7m
Amphastar Pharmaceuticals's current market capitalization is $858.1 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

210.5m251.5m255.2m240.2m294.7m322.4m349.8m

Revenue growth, %

20%1%

Cost of goods sold

159.2m174.2m151.0m149.4m187.7m190.4m206.5m

Gross profit

51.3m77.3m104.2m90.8m107.0m131.9m143.3m
Annual
USDY, 2012Y, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

50.2m53.6m67.8m66.1m72.4m65.6m86.3m73.7m92.6m

Accounts Receivable

22.9m33.2m26.8m36.0m52.2m45.4m66.0m

Prepaid Expenses

9.8m5.5m9.5m6.8m

Inventories

118.4m63.6m69.3m110.5m96.8m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(10.7m)(2.8m)10.5m4.5m(6.7m)46.5m1.1m

Depreciation and Amortization

12.0m15.4m16.5m18.1m21.5m

Inventories

9.1m(9.7m)18.7m(6.0m)(41.1m)15.3m

Accounts Payable

7.0m6.7m29.2m(11.7m)20.6m
Show all financial metrics

Amphastar Pharmaceuticals Operating Metrics

FY, 2016

Facilities

5

Products

19
Show all operating metrics

Amphastar Pharmaceuticals Revenue Breakdown

Embed Graph

Amphastar Pharmaceuticals revenue breakdown by business segment: 94.1% from Finished pharmaceutical products and 5.9% from Active Pharmaceutical Ingredients

Amphastar Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Amphastar Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Amphastar Pharmaceuticals Online and Social Media Presence

Embed Graph

Amphastar Pharmaceuticals Company Culture

  • Overall Culture

    F

    44/100

  • CEO Rating

    A

    80/100

  • Compensation

    D

    55/100

Learn more on Comparably

Amphastar Pharmaceuticals News and Updates

Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection

RANCHO CUCAMONGA, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Dextrose injection 50% in the 50 mL Luer-Jet® Prefilled Syri…

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020

Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020 Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 15th, 2021

RANCHO CUCAMONGA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2020 ended December 31, 2020, after the market closes on Monday, March 15th, 2021, and will hold a conference call t…

Amphastar Pharmaceuticals to Present at the Raymond James 2021 Institutional Healthcare Conference

RANCHO CUCAMONGA, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V…

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2020

Reports Net Revenues of $83.4 Million for the Three Months Ended September 30, 2020 Reports Net Revenues of $83.4 Million for the Three Months Ended September 30, 2020

Amphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate Injection

RANCHO CUCAMONGA, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Atropine Sulfate injection 0.1mg/mL in the 10 mL Luer-Jet® Pr…
Show more

Amphastar Pharmaceuticals Frequently Asked Questions

  • When was Amphastar Pharmaceuticals founded?

    Amphastar Pharmaceuticals was founded in 1996.

  • Who are Amphastar Pharmaceuticals key executives?

    Amphastar Pharmaceuticals's key executives are Jack Y. Zhang, Mary Z. Luo and Jacob Liawatidewi.

  • How many employees does Amphastar Pharmaceuticals have?

    Amphastar Pharmaceuticals has 2,027 employees.

  • What is Amphastar Pharmaceuticals revenue?

    Latest Amphastar Pharmaceuticals annual revenue is $349.8 m.

  • What is Amphastar Pharmaceuticals revenue per employee?

    Latest Amphastar Pharmaceuticals revenue per employee is $172.6 k.

  • Who are Amphastar Pharmaceuticals competitors?

    Competitors of Amphastar Pharmaceuticals include Synthon, Vertex Pharmaceuticals and Esteve Quimica.

  • Where is Amphastar Pharmaceuticals headquarters?

    Amphastar Pharmaceuticals headquarters is located at 11570 6th St, Rancho Cucamonga.

  • Where are Amphastar Pharmaceuticals offices?

    Amphastar Pharmaceuticals has offices in Rancho Cucamonga, Nanjing Shi and Éragny-sur-Epte.

  • How many offices does Amphastar Pharmaceuticals have?

    Amphastar Pharmaceuticals has 3 offices.